A murine pneumonia model to study pathogenesis of Stenotrophomonas maltophilia

World Journal of Microbiology and Biotechnology

Volumn 26, Issue 5, 2010, Pages 795-803

  Sharan, Riti ^a   Chhibber, Sanjay ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Murine model; Pathogenesis; Pneumonia; S. maltophilia

Indexed keywords

ALVEOLAR MACROPHAGES; ANIMAL MODEL; CLINICAL ISOLATES; GASTROINTESTINAL INFECTIONS; HISTOPATHOLOGICAL EXAMINATIONS; INFECTION MODELS; INTERSTITIAL PNEUMONINITIDES; LACTATE DEHYDROGENASE ACTIVITIES; LIPID PEROXIDATION; LUNG TISSUE; MURINE MODEL; PULMONARY INFECTIONS; RESPIRATORY TRACT; SKIN LESION; STENOTROPHOMONAS MALTOPHILIA; TISSUE DAMAGE; VIRULENCE FACTORS;

BACTERIOLOGY; BLOOD; MACROPHAGES;

PULMONARY DISEASES;

ANIMALIA; BACTERIA (MICROORGANISMS); MURINAE; MUS; STENOTROPHOMONAS MALTOPHILIA;

EID: 77952243109     PISSN: 09593993     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11274-009-0235-8     Document Type: Article

References (26)

1. Allen PM, Fisher D, Saunders JR, Hart CA (1987) The role of capsular polysaccharide K 21b of Klebsiella and of the structurally related cationic acid polysaccharide of E. coli in resistance to phagocytosis and serum killing. J Med Microbiol 24: 363-373.
2. Babior BM (1984) The respiratory burst of phagocytes. J Clin Invest 73: 599-601.
3. Bouhafs RK, Samuelson A, Jarstrand C (2003) Lipid peroxidation of lung surfactant due to reactive oxygen species released from phagocytes stimulated by bacteria from children with cystic fibrosis. Free Rad Res 37: 909-917.
4. Chhibber S, Gupta A, Sharan R, Gautam V, Ray P (2007) Putative virulence characteristics of Stenotrophomonas maltophilia: a study on clinical isolates. World J Microbiol Biotechnol 24: 2819-2825.
5. Chu KK, MacDonald KL, Davidson DJ, Speert DP (2004) Persistence of Burkholderia mutlivorans within pulmonary macrophage in the murine lung. Infect Immun 72: 6142-6147.
6. Denton M, Kerr KG (1998) Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev 11: 57-80.
7. Elting LS, Khardori N, Bodey GP, Fainstein V (1990) Nosocomial infection caused by Xanthomonas maltophilia: a case-control study of predisposing factors. Infect Control Hosp Epidemiol 11: 134-138.
8. Ensminger SA, Wright RS, Baddour LM, Afessa B (2006) Suspected ventilator associated pneumonia in cardiac patients admitted to coronary care unit. Myo Clin Proc 81: 32-35.
9. Figueiredo PMS, Furumura MT, Santos AM, Sousa ACT, Kota DJ, Levy CE, Yano T (2006) Cytotoxic activity of clinical Stenotrophomonas maltophilia. Lett Appl Microbiol 43: 443-449.
10. Holme BM, Costas TT, Stevens M (1994) Evaluation of two BBL Crystal systems for identification of some clinically important gram-negative bacilli. J Clin Microbiol 32: 2221-2224.
11. Holsclaw DS (1993) Cystic fibrosis and and pulmonary involvement from multiple perspectives. Semin Respir Infect 7: 141-150.
12. Hulisz DT, File TM (1992) Predisposing factors and antibiotic use in nosocomial infections caused by Xanthomonas maltophilia. Infect Control Hosp Epidemiol 13: 489-490.
13. Jang TN, Wang FD, Wang LH, Liu CY, Liu IM (1992) Xanthomonas maltophilia bacteremia: an analysis of 32 cases. J Formosan Med Assoc 91: 1170-1176.
14. Krcmery VJ, Pichna P, Oravcova E, Lacka J, Kukuckova E, Studena M, Grausova S, Stopkova K, Krupova I (1996) Stenotrophomonas maltophilia bacteraemia in cancer patients: report on 31 cases. J Hosp Infect 34: 75-77.
15. Micozzi A, Venditti M, Monaco M, Friedrich A, Taglietti F, Santilli S, Martino P (2000) Bacteremia due to Stenotrophomonas maltophilia in patients with hematological malignancies. Clin Infect Dis 31: 705-711.
16. Miyairi I, Franklin JA, Andreansky M, Knapp KM, Hayden RT (2005) Acute necrotizing ulcerative gingivitis and bacteremia caused by Stenotrophomonas maltophilia in an immunocompromised host. Ped Infect Dis J 24: 181-183.
17. Rumelt S, Metzgerz Z, Kariv N, Rossenberg M (1988) Clearance of Serratia marcescens from blood in mice. Role of hydrophobic versus man nose sensitive interactions. Infect Immun 56: 1167-1170.
18. Speert DP, Steen B, Hasley K, Kwan E (1999) A murine model for infection with Burkholderia cepacia with sustained persistence in the spleen. Infect Immun 67: 4027-4032.
19. Spencer RC (1995) The emergence of epidemic, multiple-antibiotic-resistant Stenotrophomonas (Xanthomonas) maltophilia and Burkholderia (Pseudomonas) cepacia. J Hosp Infect 30: 453-464.
20. Talmaciu I, Varlotta L, Mortenson J, Schidlow DV (2000) Risk factors for emergence of Stenotrophomonas maltophilia in cystic fibrosis. Pediatr Pulmonol 30: 10-15.
21. Taylor PW, Kroll HP (1983) Killing of an encapsulated strain of E. coli by human serum. Infect Immun 42: 122-131.
22. Tsai WP, Chen CL, Ko WC, Pan SC (2006) Stenotrophomonas maltophilia bacteremia in burn patients. Burns 32: 155-158.
23. Valdezate S, Vindel A, Maiz L, Baquero F, Escobar H, Canton R (2001) Persistence and variability of Stenotrophomonas maltophilia in cystic fibrosis patients, Madrid 1991-1998. Emerg Infect Dis 1: 113-122.
24. Vassault A (1983) Lactate dehydrogenase UV-method with pyruvate and NADH. In: Bergmeyer HU (ed) Methods of enzymatic analysis, Vol III, 3rd edn. Plenum, New York, 118-125.
25. Waters VJ, Gomez MI, Soong G, Amin S, Ernst R, Prince A (2007) Immunostimulatory properties of the emerging pathogen Stenotrophomonas maltophilia. Infect Immun 75: 1698-1703.
26. Wills ED (1965) Mechanism of Lipid peroxide formation in animal tissues. Biochem J 99: 667-676.